ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,93
-0,09%
Bitcoin
64 870,70
0,08%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) Actualités

AIM AIM ImmunoTech Inc

0,3935
-0,0038 (-0,96%)
20 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AIM ImmunoTech Inc AIM AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0038 -0,96% 0,3935 22:19:51
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,39 0,39 0,41 0,3935 0,3973
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
10/6/202414:55GLOBEAIM ImmunoTech to Participate in the Virtual Investor Pitch..
03/6/202416:15EDGAR2Form 8-K - Current report
03/6/202416:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/6/202415:15GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
31/5/202414:30GLOBEAIM ImmunoTech Announces Pricing of $2.0 Million Registered..
31/5/202414:14EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/5/202415:15GLOBEAIM ImmunoTech to Participate in Two Upcoming Investor..
16/5/202413:30GLOBEAIM ImmunoTech Reports First Quarter 2024 Financial Results..
15/5/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202414:50GLOBEAIM ImmunoTech to Discuss First Quarter 2024 Financial..
07/5/202414:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202414:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202414:30GLOBEAIM ImmunoTech Completes cGMP Manufacturing of Clinical..
29/4/202414:55GLOBEAIM ImmunoTech Announces First Dose Level is Generally..
25/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
18/4/202414:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/4/202414:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
11/4/202417:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
10/4/202414:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
02/4/202413:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
28/3/202413:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
26/3/202414:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
25/3/202414:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
22/3/202413:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
20/3/202414:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
15/3/202413:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
07/3/202414:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
29/2/202414:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
21/2/202416:37EDGAR2Form D/A - Notice of Exempt Offering of Securities: [Amend]
20/2/202422:31EDGAR2Form 8-K - Current report
14/2/202414:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
09/2/202421:47EDGAR2Form 8-K - Current report
08/2/202414:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
25/1/202423:00EDGAR2Form 8-K - Current report
24/1/202415:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
22/1/202414:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
10/1/202419:42EDGAR2Form 8-K - Current report
10/1/202414:45EDGAR2Form 8-K - Current report
10/1/202414:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
05/1/202419:32BWAIM Shareholders Elect All Four Company Director Nominees at..
03/1/202422:24EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202422:24EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
03/1/202422:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
29/12/202314:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/12/202314:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
28/11/202322:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/11/202322:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
27/11/202318:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202315:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
21/11/202318:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..

Dernières Valeurs Consultées

AMEX
AIM
AIM ImmunoTech
BIT
I06577
Banca Imi
AQSE
SVEN
SVentures
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés